Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)
To evaluate the rate of clinical complete response 6-8 weeks after treatment with docetaxel plus cisplatin and 5-fluorouracil followed by chemoradiotherapy and after chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck.
Head and Neck Neoplasms
DRUG: Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy|DRUG: Concomitant cisplatin, 5-FU and radiotherapy
Rate of radiologic Complete Response (CR) evaluated 6-8 weeks after the completion of treatment, from end of treatment until 6-8 weeks
Duration of response, from the date of first documented tumor response to the date of first documented tumor progression|Time to disease progression, From the date of the treatment start to the date of first documented progression of disease|Time to treatment failure, from the date of treatment start to the date of diagnosis of progression, withdrawal from study treatment for any reason, administration of other antitumor treatment, or death for any cause|Median length of overall survival, time interval from the date of treatment to the date of death
To evaluate the rate of clinical complete response 6-8 weeks after treatment with docetaxel plus cisplatin and 5-fluorouracil followed by chemoradiotherapy and after chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck.